Marc Banjak - 28 Jan 2026 Form 4 Insider Report for iBio, Inc. (IBIO)

Reporting relationship: Chief Legal Officer
Issuer ticker: IBIO
Reported as of: 28 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jan 2026, 06:16:28 UTC
Prior SEC filing: 22 Oct 2025
Next SEC filing: 27 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Marc Banjak

Key filing fact

Marc Banjak filed Form 4 for iBio, Inc. (IBIO) on 30 Jan 2026.

Key facts

This page summarizes Marc Banjak's Form 4 filing for iBio, Inc. (IBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Jan 2026, 06:16.

Change

Previous filing in this sequence was filed on 22 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002033869 Primary reporting owner

Banjak Marc

Relationship: Chief Legal Officer
Address: C/O IBIO, INC.,, 11750 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO
Signature: /s/ Marc Banjak
Signature date: 30 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IBIO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +146,000
Change %
Price: $0.000000
Shares after: 146,000
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 146,000
Exercise price: $2.23
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.